A significant shift in Medicare drug coverage is underway. Starting July 1, 2026, the
Medicare GLP-1 Bridge program will temporarily allow coverage of certain weight-loss medications — including Wegovy, Zepbound (KwikPen formulation), and Foundayo — for eligible Medicare Part D beneficiaries.
For many seniors who have struggled with the high cost of these medications, this pilot program represents one of the most notable changes to Medicare prescription coverage in years.
Why This Program Matters
Historically, Medicare has been prohibited by law from covering drugs prescribed specifically for weight loss. That long-standing restriction has put GLP-1 medications financially out of reach for many beneficiaries, with cash prices that can range from roughly $150 to nearly $700 per month, depending on the drug and dosage.
The Bridge program is designed to fill that coverage gap on a short-term basis while the Centers for Medicare & Medicaid Services (CMS) studies whether broader access could improve long-term health outcomes.
How the Bridge Program Works
The Medicare GLP-1 Bridge will run from
July 1, 2026, through December 31, 2027. Here's a quick overview:
- Covered medications (as of June, 2026): Wegovy (injection and tablets), the KwikPen formulation of Zepbound, and Foundayo
- Monthly copay: A flat $50 per prescription, regardless of dosage
- Eligibility requirement: Enrollment in a Medicare Part D standalone plan or a Medicare Advantage plan with drug coverage (MA-PD). See the next section for additional eligibility criteria.
- Prior authorization: Required, submitted by your prescribing provider
- Processing: Handled through a centralized CMS system rather than individual Part D plans
Because the program operates outside the standard Part D benefit, prescribers and pharmacies will route claims through a central processor designated by CMS.
Who May Be Eligible
Eligibility is based on body mass index (BMI) and related health conditions. According to CMS, a beneficiary must be at least 18 years old and fall into one of these clinical categories at the time GLP-1 therapy is initiated:
- BMI of 35 or higher (no additional condition required); or
- BMI of 30 or higher, plus a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease (stage 3a or higher); or
- BMI of 27 or higher, plus a diagnosis of pre-diabetes, previous heart attack, previous stroke, or symptomatic peripheral artery disease
The medication must also be prescribed alongside structured lifestyle modifications, including nutrition and physical activity guidance consistent with FDA-approved labeling.
It's important to note that beneficiaries already taking GLP-1 drugs for Medicare-covered health conditions such as Type 2 diabetes or certain cardiovascular indications will continue to access those medications through their existing Part D plan. The Bridge program is specifically for weight-loss prescriptions.
A Quick Look at GLP-1 Medications
This class of drugs, GLP-1 receptor agonists, mimic a hormone that helps regulate blood sugar and appetite. They slow digestion, help people feel full longer, and may support meaningful weight reduction when combined with lifestyle changes.
For beneficiaries with weight-related health concerns, sustained weight loss may help with:
- Heart disease
- High blood pressure
- Type 2 diabetes
- Sleep apnea
- Joint problems
As with any medication, GLP-1 drugs carry potential side effects and aren't right for everyone. Conversations with a qualified provider are essential.
Important Limitations to Understand
While the Bridge program offers significant savings, there are a few notable trade-offs:
- The $50 copay
does not count toward the Part D deductible or the annual out-of-pocket prescription drug spending cap
- Part D low-income subsidies (Extra Help) cannot be applied to these prescriptions
- The program is temporary (for now), ending December 31, 2027
- Studies suggest many people regain weight after stopping GLP-1 therapy, which raises important planning considerations once the program concludes
What Happens After 2027
CMS originally designed the Bridge as a transition to a longer-term initiative called the
BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth). However, the timeline and structure of that model are still evolving, and ongoing access to GLP-1s for weight loss beyond 2027 is not yet guaranteed.
Beneficiaries who benefit from the Bridge program will want to review their drug plan options carefully during future Annual Enrollment Periods to understand what coverage may be available.
Recap
The Medicare GLP-1 Bridge represents a temporary, targeted opportunity for eligible Part D beneficiaries to access weight-loss medications at a more predictable cost. Like any pilot program, the details may continue to evolve as CMS releases additional guidance.
If you think you may qualify, the best first step is a conversation with your health care provider about whether a GLP-1 medication fits your overall health picture. For program specifics, visit
CMS.gov or
Medicare.gov, or call 1-800-MEDICARE (1-800-633-4227).
